Lakefront Biotherapeutics | GLPG - Equity Capital And Reserves


Lakefront Biotherapeutics reported EUR3.25B in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
argenx SE USD 8.42B 1.09B Jun/2026
AstraZeneca USD 50.3B 2.96B Jun/2026
Biogen USD 18.85B 196.3M Jun/2026
Genmab DKK 5.85B 96M Dec/2025
Gilead Sciences USD 11.74B 11.77B Jun/2026
GlaxoSmithKline GBP 17.64B 223M Jun/2026
GRIFOLS EUR 7.98B 2.52B Jun/2026
Hikma Pharmaceutical USD 2.59B 42M Dec/2025
Incyte USD 6.34B 721.58M Jun/2026
Merck EUR 29.74B 1.15B Mar/2026
Neurocrine Biosciences USD 3.69B 286.2M Jun/2026
Novartis USD 41.95B 3.02B Jun/2026
Roche Holding CHF 32.69B 1.11B Jun/2026
Sanofi EUR 69.57B 3.24B Jun/2026
UCB EUR 10.87B 1.18B Dec/2025
Vertex Pharmaceuticals USD 20.25B 886M Jun/2026